Microbot Medical Inc.
No SEC Form 4 filings for $MBOT in the last 30 days.
See all $MBOT insider activity →H.C. Wainwright maintained a $12 price target for Microbot Medical (MBOT) after new patent approvals in the U.S., Japan, China, and Canada. The stock is near its 52-week low at $0.95. Q2 2026 revenue grew 100% to $241,000, but net loss widened to $5.6 million. The company signed a distribution deal in Israel and aims for European market entry.
Microbot Medical (MBOT) received patents in the U.S., Japan, China, and Canada for its LIBERTY Endovascular Robotic System. The company now has 44 issued patents and 49 pending applications. These approvals support its strategy for market entry into the EU and other regions, with the company pursuing a CE Mark for international expansion. The LIBERTY system is FDA-cleared and designed to reduce radiation exposure and physical strain in vascular procedures.
Microbot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical ® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international market
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning MBOT (Microbot Medical Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent MBOT coverage spans financial news, earnings and corporate actions.
Analyst maintains buy rating with a high price target despite recent loss, suggesting upside potential.
The patent approvals validate the company's technology and may support future sales growth, but the immediate market impact is likely modest.
The new patents strengthen Microbot's IP position and could support future market expansion, likely providing modest upside pressure.
The deal expands market reach and could lift revenue outlook.
The agreement expands Microbot's international footprint and may boost near‑term sales outlook.
AlphAI scores every news story that mentions MBOT with an AI model for sentiment and relevance, and aggregates insider trades from Microbot Medical Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
H.C. Wainwright maintained a $12 price target for Microbot Medical (MBOT) after new patent approvals in the U.S., Japan, China, and Canada. The stock is near its 52-week low at $0.95. Q2 2026 revenue grew 100% to $241,000, but net loss widened to $5.6 million. The company signed a distribution deal in Israel and aims for European market entry.
2 min readMicrobot Medical (MBOT) received patents in the U.S., Japan, China, and Canada for its LIBERTY Endovascular Robotic System. The company now has 44 issued patents and 49 pending applications. These approvals support its strategy for market entry into the EU and other regions, with the company pursuing a CE Mark for international expansion. The LIBERTY system is FDA-cleared and designed to reduce radiation exposure and physical strain in vascular procedures.
1 min readMicrobot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical ® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property Portfolio The Company now holds 44 issued patents and 49 pending patents globally. Commercialization continues to advance across both U.S. and international market
1 min readMicrobot Medical (MBOT) signed a 3-year exclusive deal with Medtechnica to distribute its LIBERTY system in Israel. The company received regulatory approval in May 2026 and expects initial orders in Q4 2026. This deal supports Microbot's international expansion and scaling plans.
1 min readMicrobot Medical Inc. (MBOT) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Microbot Medical ® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel Medtechnica Ltd., a Leading Medical Device Distributor in Israel, Authorized to Distribute the LIBERTY® Endovascular Robotic System Throughout Israel Microbot Med
1 min readMicrobot Medical Inc. (MBOT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement The information set forth in Item 5.02 below is incorporated herein by reference into this Item 1.01. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On August 6
3 min readMicrobot Medical (Nasdaq: MBOT) reported Q2 2026 revenue and new-customer growth of more than 100% vs Q1 2026, citing the LIBERTY System’s full market release on April 13. The company says procedure volumes rose at prior limited-release sites, expanded U.S. sales territories from 4 to 8 (target 12 by year-end), added a federal-services agreement, and received Israeli marketing clearance.
3 min readMicrobot Medical Inc. has appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia (EMEA) to accelerate commercial readiness in these international markets. This move follows the successful U.S. market release of its LIBERTY Endovascular Robotic System and aims to leverage the system's FDA clearance and anticipated CE mark approval by the end of 2026 for global expansion. Tamir will lead the EMEA sales strategy, focusing on go-to-market strategies, distribution, and strategic partnerships, seeing significant growth opportunities comparable to the U.S. market.
3 min readMicrobot Medical (Nasdaq: MBOT) has appointed Alon Tamir as Vice President of Sales for EMEA to spearhead the commercialization of its LIBERTY Endovascular Robotic System in Europe, the Middle East, and Asia. The company, which gained FDA clearance in September 2025 and completed its U.S. market release, expects CE mark approval by the end of 2026, targeting Europe's estimated 2.3 million peripheral endovascular procedures. This strategic hire aims to establish regulatory, operational, and commercial capabilities to capitalize on significant international growth opportunities.
4 min readMicrobot Medical Inc. filed a Form 424B5 prospectus supplement to offer and sell up to $39,230,691 of common stock through H.C. Wainwright & Co. as its sales agent. The company plans to use the net proceeds for the continued development, commercialization, and regulatory activities for its LIBERTY Robotic System, expansion of its intellectual property portfolio, potential acquisitions, and general corporate purposes. This offering is subject to various risk factors detailed in the document, including potential dilution for new investors.
4 min read
